Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
DEPP autophagy regulator 1 (DEPP1) is a stress-inducible protein involved in the modulation of autophagy, particularly under conditions of fasting, metabolic stress, and hypoxia. It contains a SNARE coiled-coil homology domain and a peroxisomal targeting signal, allowing localization to mitochondria and peroxisomes. DEPP1 is directly regulated by HIF and FOXO transcription factors, and is necessary and sufficient for hypoxia-induced autophagy, mitochondrial and peroxisomal turnover, and triglyceride deposition, especially in cardiomyocytes. Loss of DEPP1 is protective in models of heart disease and insulin resistance, and its overexpression correlates with pathologies such as cancer and osteoarthritis. DEPP1’s molecular function is distinct from core autophagy machinery; it acts independently of mTOR inhibition and links metabolic stress signaling to organelle-specific autophagy.
Drugs activating HIF (such as FG-4592) indirectly increase DEPP1 expression, promoting autophagy and lipid accumulation in cardiomyocytes. DEPP1 acts as a downstream effector of FOXO-mediated and HIF-mediated autophagy.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on DEPP autophagy regulator 1 (DEPP1).